Marker Therapeutics Statistics
Share Statistics
Marker Therapeutics has 10.71M shares outstanding. The number of shares has increased by 20.27% in one year.
| Shares Outstanding | 10.71M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 20% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 7.06M |
| Failed to Deliver (FTD) Shares | 252 |
| FTD / Avg. Volume | 0.44% |
Short Selling Information
The latest short interest is 70.00K, so 0.65% of the outstanding shares have been sold short.
| Short Interest | 70.00K |
| Short % of Shares Out | 0.65% |
| Short % of Float | 0.99% |
| Short Ratio (days to cover) | 1.55 |
Valuation Ratios
The PE ratio is -3.45 and the forward PE ratio is -2.55.
| PE Ratio | -3.45 |
| Forward PE | -2.55 |
| PS Ratio | 14.63 |
| Forward PS | 13.6 |
| PB Ratio | 3.45 |
| P/FCF Ratio | -2.95 |
| PEG Ratio | n/a |
Enterprise Valuation
Marker Therapeutics Inc. has an Enterprise Value (EV) of 33.34M.
| EV / Earnings | -2.37 |
| EV / Sales | 10.07 |
| EV / EBITDA | -2.83 |
| EV / EBIT | -2.29 |
| EV / FCF | -2.03 |
Financial Position
The company has a current ratio of 5.57, with a Debt / Equity ratio of 0.
| Current Ratio | 5.57 |
| Quick Ratio | 5.57 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1% and return on capital (ROIC) is -103.79%.
| Return on Equity (ROE) | -1% |
| Return on Assets (ROA) | -0.82% |
| Return on Capital (ROIC) | -103.79% |
| Revenue Per Employee | 413.89K |
| Profits Per Employee | -1.76M |
| Employee Count | 8 |
| Asset Turnover | 0.19 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 3.67K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -45.61% in the last 52 weeks. The beta is 1.49, so Marker Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.49 |
| 52-Week Price Change | -45.61% |
| 50-Day Moving Average | 3.51 |
| 200-Day Moving Average | 3.88 |
| Relative Strength Index (RSI) | 33.92 |
| Average Volume (20 Days) | 57.01K |
Income Statement
In the last 12 months, Marker Therapeutics had revenue of 3.31M and earned -14.05M in profits. Earnings per share was -1.93.
| Revenue | 3.31M |
| Gross Profit | -7.11M |
| Operating Income | -14.58M |
| Net Income | -14.05M |
| EBITDA | -11.79M |
| EBIT | -14.58M |
| Earnings Per Share (EPS) | -1.93 |
Balance Sheet
The company has 15.11M in cash and 0 in debt, giving a net cash position of 15.11M.
| Cash & Cash Equivalents | 15.11M |
| Total Debt | 0 |
| Net Cash | 15.11M |
| Retained Earnings | -436.29M |
| Total Assets | 10.91M |
| Working Capital | 7.45M |
Cash Flow
In the last 12 months, operating cash flow was -16.44M and capital expenditures 0, giving a free cash flow of -16.44M.
| Operating Cash Flow | -16.44M |
| Capital Expenditures | 0 |
| Free Cash Flow | -16.44M |
| FCF Per Share | -1.87 |
Margins
Gross margin is -214.6%, with operating and profit margins of -440.37% and -424.2%.
| Gross Margin | -214.6% |
| Operating Margin | -440.37% |
| Pretax Margin | -424.09% |
| Profit Margin | -424.2% |
| EBITDA Margin | -356.14% |
| EBIT Margin | -440.37% |
| FCF Margin | -496.51% |
Dividends & Yields
MRKR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -75.98% |
| FCF Yield | -60.42% |
Analyst Forecast
The average price target for MRKR is $19, which is 648% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $19 |
| Price Target Difference | 648% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Jan 27, 2023. It was a backward split with a ratio of 1:10.
| Last Split Date | Jan 27, 2023 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -53.92 |
| Piotroski F-Score | 3 |